An Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Glofitamab (Primary) ; Obinutuzumab (Primary) ; RG 6333 (Primary) ; RG 6333 (Primary) ; Tocilizumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
- Focus Adverse reactions; First in man
- Sponsors Roche
Most Recent Events
- 24 Jul 2024 Status changed from recruiting to discontinued.
- 27 Sep 2023 Planned End Date changed from 1 Apr 2024 to 30 Apr 2025.
- 27 Sep 2023 Planned primary completion date changed from 1 Apr 2024 to 30 Apr 2025.